Exuma Biotechnology is at the forefront of developing innovative cell and gene therapies aimed at improving patient outcomes in the treatment of solid and hematological tumors. Their proprietary technologies include the rPOC Subcutaneous (SC) platform, which is designed to optimize the efficacy and safety of CAR-T therapies while eliminating the need for lymphodepleting chemotherapy. This platform allows for the administration of autologous cell therapies in non-tertiary care settings, thereby enhancing patient access to advanced treatments. Additionally, Exuma's GCAR platform focuses on in vivo CAR-T therapy, enabling the direct administration of lentivectors that target T cells, leading to enhanced proliferation and cytotoxicity without the complexities of traditional manufacturing processes.

Key innovations from Exuma include the FITNESS DRIVER, a synthetic protein that enhances the proliferation and persistence of CAR+ cells, and Tumor Metabolism Regulated (TMR) CARs, which expand the range of targets beyond conventional blood cancer antigens. The company is also advancing the use of CD3-Targeted lentivectors to selectively load lymphocytes for improved therapeutic outcomes. These technologies collectively aim to address the limitations of existing cell therapies, providing safer, more effective, and scalable treatment options for patients with significant unmet clinical needs.

United States

EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market cell & gene therapies for the treatment of cancer. Founded in 2015, The company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and headquarters in West Palm Beach, FL.

Exuma Biotechnology

Company Details